Climb Bio Inc - Asset Resilience Ratio
Climb Bio Inc (CLYM) has an Asset Resilience Ratio of 38.99% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CLYM total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Climb Bio Inc's Asset Resilience Ratio has changed over time. See what is Climb Bio Inc's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Climb Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Climb Bio Inc (CLYM) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $65.39 Million | 38.99% |
| Total Liquid Assets | $65.39 Million | 38.99% |
Asset Resilience Insights
- Very High Liquidity: Climb Bio Inc maintains exceptional liquid asset reserves at 38.99% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Climb Bio Inc Industry Peers by Asset Resilience Ratio
Compare Climb Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Climb Bio Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Climb Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 38.99% | $65.39 Million | $167.74 Million | +9.66pp |
| 2024-12-31 | 29.32% | $63.69 Million | $217.19 Million | +16.94pp |
| 2023-12-31 | 12.39% | $13.69 Million | $110.47 Million | -46.86pp |
| 2022-12-31 | 59.25% | $79.98 Million | $134.99 Million | +7.55pp |
| 2021-12-31 | 51.70% | $89.56 Million | $173.24 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $24.63 Million | -- |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the co… Read more